Milestone Pharmaceuticals announced a workforce reduction of about 20%, expected to be completed by the first quarter of 2027. The company says broader efficiency measures are intended to lower operating expenses by roughly 30%. CFO Amit Hasija resigned effective November 13, 2026. VP of Finance Anthony Krick is serving as principal financial and accounting officer while the company searches for a replacement CFO. CMO David Bharucha’s role ended November 12 as part of the restructuring; he is transitioning to a consulting/advisory role with the company. The cuts aim to extend Milestone’s cash runway into late 2028 as it develops its heart-rhythm treatment CARDAMYST and advances clinical work. The company expects about $2 million in one-time restructuring-related costs. CARDAMYST generated $1 million in Q3 sales, up 73% from the prior quarter. The company reported a $25.8 million quarterly net loss, underscoring the financial pressure behind the cost reductions. Sources: Mil...
- Get link
- X
- Other Apps